Propoxyphene

CHEMBL1213351 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
339.5 g/mol
LogP
4.2
Phase
4

Propoxyphene is a synthetic opioid analgesic of the diphenylheptane class that acts primarily as a mu-opioid receptor agonist to produce analgesia, sedation, and euphoria, with potency approximately half that of codeine. It was used for mild to moderate pain management but was withdrawn globally due to its cardiac toxicity, particularly QT prolongation and potentially fatal arrhythmias even at therapeutic doses.

Masse moléculaire

339,5000 g/mol

LogP

4,20

TPSA

29,50 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C

InChI

InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1

Molecular Formula

C22H29NO2

HBD / HBA

- / 3

Liaisons Rotatives

9

Atomes Lourds

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Propoxyphene is a synthetic opioid analgesic of the diphenylheptane class that acts primarily as a mu-opioid receptor agonist to produce analgesia, sedation, and euphoria, with potency approximately half that of codeine. It was used for mild to moderate pain management but was withdrawn globally due to its cardiac toxicity, particularly QT prolongation and potentially fatal arrhythmias even at therapeutic doses.

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Yes, Propoxyphene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1213351. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10100. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.